Jay Elliott Biography and Net Worth

COO of Adicet Bio

Jay P. Elliott is the Chief Operating Officer at Installed Building Products Inc.

What is Jay P. Elliott's net worth?: The estimated net worth of Jay P. Elliott is at least $30,985.71 as of March 8th, 2023. Mr. Elliott owns 32,490 shares of Adicet Bio stock worth more than $30,986 as of November 21st. This net worth evaluation does not reflect any other investments that Mr. Elliott may own. Learn More about Jay P. Elliott's net worth.
How do I contact Jay P. Elliott?: The corporate mailing address for Mr. Elliott and other Adicet Bio executives is 4 TRI HARBOR COURT, PORT WASHINGTON NY, 11050. Adicet Bio can also be reached via phone at (650) 503-9095 and via email at [email protected]. Learn More on Jay P. Elliott's contact information.
Has Jay P. Elliott been buying or selling shares of Adicet Bio?: Jay P. Elliott has not been actively trading shares of Adicet Bio during the past quarter. Learn More on Jay P. Elliott's trading history.
Who are Adicet Bio's active insiders?: Adicet Bio's insider roster includes Chen BA (), Jay Elliott (COO), Aya Jakobovits (Director), Chen Schor (CEO), and Andrew Sinclair (Director). Learn More on Adicet Bio's active insiders.
Are insiders buying or selling shares of Adicet Bio?: In the last twelve months, Adicet Bio insiders bought shares 1 times. They purchased a total of 3,125,000 shares worth more than $7,500,000.00. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 5,900 shares worth more than $8,437.00. The most recent insider tranaction occured on June, 5th when Director Michael Kauffman sold 5,900 shares worth more than $8,437.00. Insiders at Adicet Bio own 19.1% of the company. Learn More about insider trades at Adicet Bio.
Information on this page was last updated on 6/5/2024.

Jay P. Elliott Insider Trading History at Adicet Bio

Jay P. Elliott Buying and Selling Activity at Adicet Bio

Adicet Bio Company Overview

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.

Today's Range

Now: $0.95

$0.92

$0.98

50 Day Range

MA: $1.36

$0.95

$1.53

2 Week Range

Now: $0.95

$0.92

$3.77

Volume

505,295 shs

Average Volume

1,102,834 shs

Market Capitalization

$78.58 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.81

Missed Nvidia? Watch this ASAP

From Brownstone Research | Ad

Click here and I’ll tell you everything you need to know.